$0.39
+0.00 (+0.95%)
Open$0.39
Previous Close$0.39
Day High$0.43
Day Low$0.39
52W High$1.01
52W Low$0.22
Volume—
Avg Volume316.6K
Market Cap6.41M
P/E Ratio—
EPS$-0.61
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+4,945.7% upside
Current
$0.39
$0.39
Target
$19.88
$19.88
$13.54
$19.88 avg
$24.91
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 139.9K | 138.5K | 653.1K |
| Net Income | -8,204,868 | -7,311,992 | 116.0K |
| Profit Margin | -5,863.7% | -5,570.5% | 17.8% |
| EBITDA | -8,510,680 | -8,005,887 | 172.6K |
| Free Cash Flow | — | — | 101.3K |
| Rev Growth | +1.0% | +1.0% | -9.1% |
| Debt/Equity | — | — | 0.30 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |